Aromasin is an aromatase inhibitor used in hormone therapy for breast cancer. It blocks the enzyme aromatase which converts androgens to estrogens in postmenopausal women. By reducing systemic estrogen levels it slows the growth of estrogen dependent tumor cells. The drug binds to the active site of aromatase preventing its catalytic activity. This decrease in estrogen production leads to lowered stimulation of estrogen receptors on tumor cells. The overall therapeutic effect is tumor growth inhibition and improved clinical outcomes in appropriate patients.

Aromasin is the brand name for the oral steroidal aromatase inhibitor exemestane. It is primarily used in the treatment of hormone receptor positive breast cancer in postmenopausal women. The drug works by irreversibly blocking the aromatase enzyme, which reduces the production of estrogen in peripheral tissues. By lowering systemic estrogen levels, Aromasin deprives estrogen dependent tumor cells of proliferative signals. This inhibition leads to decreased estrogen mediated transcription of genes involved in cell growth and survival. The resulting hormonal environment shifts the balance toward apoptosis and reduced tumor progression. Consequently, Aromasin provides a targeted therapeutic effect that complements surgical and radiation interventions in appropriate clinical settings.

Headache is commonly reported by individuals taking certain oral medications. Nausea frequently appears as a side effect in clinical observations. Dizziness is another frequently observed symptom in patients. Fatigue often follows medication use without indicating a serious problem. Dry mouth is regularly noted in user reports. Muscle aches have been described as a mild adverse response. Occasional low-grade fever may appear in some cases.

Headache is frequently reported among users of certain medications. Dizziness may occur especially when standing up quickly. Nausea is a common gastrointestinal symptom observed in many cases. Fatigue or tiredness often accompanies treatment periods. Skin rash or mild irritation can develop at application sites. Some individuals experience changes in appetite or weight.